Is interleukin-17 implicated in early knee osteoarthritis pathogenesis as in rheumatoid arthritis?

[1] Van Steenbergen HW(2018)Preventing progression from arthralgia to arthritis: targeting the right patients Nat Rev Rheumatol 14 32-41

[2] da Silva JAP(2016)Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future Osteoarthritis Cartilage 24 2013-2021

[3] Huizinga TWJ(2016)Strategies for the prevention of knee osteoarthritis Nat Rev Rheumatol 12 92-101

[4] Karsdal MA(2010)IL-17 in cutaneous lupus erythematosus Eur J Intern Med 21 202-207

[5] Michaelis M(2014)Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies Clin Res Hepatol Gastroenterol 38 491-498

[6] Ladel C(2014)Pathogenic role of IL-17 in psoriasis and psoriatic arthritis Actas Dermosifiliogr 105 9-20

[7] Roos EM(2013)Role of IL-17 in psoriasis and psoriatic arthritis Clin Rev Allergy Immunol 44 183-193

[8] Arden NK(2014)Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters Inflammopharmacology 22 295-303

[9] Tanasescu C(2014)The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes Glia 62 725-735

[10] Balanescu E(2013)Cytokine profile in relapsingremitting multiple sclerosis patients and the association between progression and activity of the disease Mol Med Rep 7 1010-1020

[1] Van Steenbergen HW(2018)Preventing progression from arthralgia to arthritis: targeting the right patients Nat Rev Rheumatol 14 32-41

[2] da Silva JAP(2016)Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future Osteoarthritis Cartilage 24 2013-2021

[3] Huizinga TWJ(2016)Strategies for the prevention of knee osteoarthritis Nat Rev Rheumatol 12 92-101

[4] Karsdal MA(2010)IL-17 in cutaneous lupus erythematosus Eur J Intern Med 21 202-207

[5] Michaelis M(2014)Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies Clin Res Hepatol Gastroenterol 38 491-498

[6] Ladel C(2014)Pathogenic role of IL-17 in psoriasis and psoriatic arthritis Actas Dermosifiliogr 105 9-20

[7] Roos EM(2013)Role of IL-17 in psoriasis and psoriatic arthritis Clin Rev Allergy Immunol 44 183-193

[8] Arden NK(2014)Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters Inflammopharmacology 22 295-303

[9] Tanasescu C(2014)The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes Glia 62 725-735

[10] Balanescu E(2013)Cytokine profile in relapsingremitting multiple sclerosis patients and the association between progression and activity of the disease Mol Med Rep 7 1010-1020